Bristol Projects Opdivo Sales Will Grow Again In 2021

With new Opdivo/Yervoy combination data in first-line lung cancer, the company expects the PD-1 inhibitor’s growth to go from flat to rising in 2021. Bristol’s and Celgene’s third quarter earnings exceeded expectations and their merger is on track to close this year.

SC1910_Lung Cancer_47781766_1200.jpg
Bristol expects first-line lung cancer to boost Opdivo sales starting in 2021. • Source: Shutterstock

Bristol-Myers Squibb Co. is optimistic that one-time PD-1 inhibitor market leader Opdivo (nivolumab) can return to growth in 2021 now that its Opdivo/Yervoy (ipilimumab) combination has delivered positive overall survival results in two first-line lung cancer studies, the company said during its 31 October third quarter earnings call.

But even with Opdivo sales flattening out due to competition from Merck & Co. Inc.’s anti-PD-1 drug Keytruda (pembrolizumab)...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Earnings

Merck & Co.’s Winrevair Growing Into The Revenue Driver Needed Post-Keytruda LOE

 
• By 

PAH drug Winrevair generated more than $1bn in sales in its first year on the US market, but the company plans to cut $3bn in costs through 2027 that it will reinvest in additional growth drivers.

Novo Selects Internal CEO To Recharge Growth

 

Maziar Mike Doustdar has led the company’s international operations and will succeed Lars Fruergaard Jørgensen on August 7.

CEO Underlines AstraZeneca’s Increasingly US-Centric Growth Plans

 

Its multibillion dollar investment demonstrates the importance of the US to AstraZeneca, with half of its targeted $80bn revenues by 2030 set to come from the country, Pascal Soriot said as it presented strong second-quarter results.

EU 15% Tariff Deal Still Leaves Questions For Pharma

 

A single 15% tariff rate on imports from Europe includes pharmaceuticals, but it remains unclear if the trade deal will exclude generics or if Trump will offer a grace period.

More from Business

Analysts Not Impressed With Adaptimmune’s Survival Attempts

 
• By 

The company is getting just $55m from the sale of Tecelra and a couple of late-stage T-cell therapies to US WorldMeds.

Bristol Myers Shifts Five Drugs To Bain-Partnered Immunology Venture

 
• By 

Bristol Myers and Bain will form a new company focused on five immunology drugs that Cantor Fitzgerald analysts say have been off investors’ radar.

Finance Watch: MapLight’s Mega-Round Funds Exploration Of Its Cobenfy Competitor

 
• By 

Private Company Edition: MapLight raised a $372.5m series D round to fund ongoing Phase II trials and investigation of additional indications for its M1/M4 muscarinic agonist. Also, Scrip spoke with Modi Ventures about its new fund.